Skip to main content

Taxotere MDL Update: Discovery stage in progress

Taxotere MDL Update: Discovery stage in progress

Taxotere MDL Update: Discovery stage in progress

Introduction

Taxotere: – MDL No. 2740: in Re Taxotere (Docetaxel) Products Liability Litigation was created on October 4, 2016, under Judge Kurt D. Engelhardt in the Eastern District of Louisiana; the bellwether trial dates are set for January 28, 2019; April 8, 2019; July 15, 2019; and November 4, 2019. There are 7,500 cases filed under this MDL as per the 26th January Joint Status Report submitted by both the parties. The Plaintiffs of the currently pending cases were ordered to produce product information as per the Case Management Report dated 12th January, to be submitted within a period of 15 days from the Order entry date. The rest of the Plaintiffs will have 30 days in hand once a Short Form Complaint has been filed by them with the Court.

A permanent alopecia lawsuit was filed against Sanofi over its chemotherapy drug’s side effects by a Pennsylvania woman in the U.S. District Court for the Eastern District of Louisiana. Allegations included including failure to warn, negligence, fraudulent misrepresentation and concealment, and several others.

Comments

Restricted HTML

  • Allowed HTML tags: <a href hreflang> <em> <strong> <cite> <blockquote cite> <code> <ul type> <ol start type> <li> <dl> <dt> <dd> <h2 id> <h3 id> <h4 id> <h5 id> <h6 id>
  • Lines and paragraphs break automatically.
  • Web page addresses and email addresses turn into links automatically.

Latest News

First Federal Bellwether Trial Set in Strattice Mesh Case

Categories: Hernia Mesh

Lawyers involved in federal Strattice hernia mesh litigation are scheduled to meet with the presiding judge in the U.S. District Court for the District of New Jersey to…

Tepezza Hearing Loss Trial Set for June 2026

Categories: Tepezza

The U.S. District Judge overseeing all federal Tepezza lawsuits has postponed the start of the first bellwether trial by 60 days.

This decision comes as attorneys…

FDA Moves to Restrict Dangerous 7-OH Opioid Products

Categories: Opioids

In a significant move to combat the ongoing opioid crisis, the U.S. Food and Drug Administration (FDA) has recommended a scheduling action under the Controlled Substances Act (CSA) to regulate certain products containing 7-hydroxymitragynine (7-…

✍️ FREE — 2,800 Pages Legal Process Outsourcing Trial!                 
No Contract. No Risk — Full Mass Tort + LPO Access, Free!

Only 10 Firms Accepted—Offer Ends August 31!